

Erratum to identification of GPX4 as a therapeutic target for lung adenocarcinoma after EGFR-TKI resistance

Editorial Office

Translational Lung Cancer Research

Correspondence to: Editorial Office. Translational Lung Cancer Research. Email: editor@tlcr.org.

Submitted Jun 20, 2022, Accepted for publication Jul 22, 2022 doi: 10.21037/tlcr-2022-4


View this article at: https://dx.doi.org/10.21037/tlcr-2022-4

Erratum to: Transl Lung Cancer Res 2022;11:786-801


This article (1) titled "Identification of GPX4 as a therapeutic target for lung adenocarcinoma after EGFR-TKI resistance" (doi: 10.21037/tlcr-22-318), unfortunately contains errors in *Figure 2D* and *Figure 7A*. The bands of KEAP1 in *Figure 2D* should be 13, and "Osimertinib" in *Figure 7A* should be "Gefitinib". The correct *Figure 2* and *Figure 7* can be found below.

1732 Editorial Office. Erratum

Correct Figure 2:



Correct Figure 7:



The authors apologize for the oversight.

Click here to view the updated version of the article.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References

1. Zhang C, Wang C, Yang Z, et al. Identification of GPX4 as a therapeutic target for lung adenocarcinoma after EGFR-TKI resistance. Transl Lung Cancer Res 2022;11:786-801.

Cite this article as: Editorial Office. Erratum to identification of GPX4 as a therapeutic target for lung adenocarcinoma after EGFR-TKI resistance. Transl Lung Cancer Res 2022;11(8):1731-1733. doi: 10.21037/tlcr-2022-4